Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease.

Hoertel, Nicolas; Boulware, David R; Sánchez-Rico, Marina; Burgun, Anita; Limosin, Frédéric

Hoertel, Nicolas; Boulware, David R; Sánchez-Rico, Marina; Burgun, Anita; Limosin, Frédéric.

Hoertel N; Université Paris Cité, Paris, France.
Boulware DR; INSERM U1266, Institut de Psychiatrie et Neuroscience de Paris, Paris, France.
Sánchez-Rico M; Assistance Publique-Hôpitaux de Paris, DMU Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
Burgun A; Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis.
Limosin F; Assistance Publique-Hôpitaux de Paris, DMU Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.

JAMA Netw Open ; 5(11): e2242140, 2022 Nov 01.

Article in English | MEDLINE | ID: covidwho-2116969

This cohort study examines the prevalence of contraindications to nirmatrelvir-ritonavir in patients hospitalized with COVID-19.

Subject(s)

COVID-19; Ritonavir; Humans; Ritonavir/therapeutic use; Prevalence; Contraindications; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ritonavir / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Language: English Journal: JAMA Netw Open Year: 2022 Document Type: Article Affiliation country: Jamanetworkopen.2022.42140

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google